![Jonathan Poole](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: 43 537 $ in data 31/05/2026
Jonathan Michael Poole is Director at ACADIA Pharmaceuticals, Inc. since 2026.
Mr. Poole is Senior Vice President-Finance at Vertex Pharmaceuticals, Inc. since 2020.
Former roles include Independent Director at Codiak BioSciences, Inc., Senior Vice President at Shire Plc from 2006 to 2014, Chief Financial & Accounting Officer at Genocea Biosciences, Inc. from 2014 to 2018, Investment Manager at Avanti Capital PLC, Investment Manager at Odyssey Partners Ltd. from 2004 to 2007, Head-Strategic Planning & Portfolio Management at Shire Human Genetic Therapies, Inc., and Chief Financial Officer & Treasurer at Evelo Biosciences, Inc. from 2018 to 2020.
Education includes an undergraduate degree from the University of Durham and an MBA from London Business School.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 29/05/2026 | 2.010 ( 0% ) | 43 537 $ | 31/05/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| ACADIA PHARMACEUTICALS INC. | Direttore/Membro del Consiglio | 03/03/2026 |
| VERTEX PHARMACEUTICALS INCORPORATED | Corporate Officer/Principal | 01/03/2020 |
| Società | Posizione | Fine |
|---|---|---|
| EVELO BIOSCIENCES, INC. | Direttore Finanziario/CFO | 27/03/2020 |
| GENOCEA BIOSCIENCES, INC. | Direttore Finanziario/CFO | 23/03/2018 |
Shire Plc /Old/
 Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Develops, manufactures and markets pharmaceuticals | Corporate Officer/Principal | 01/03/2014 |
Odyssey Partners Ltd.
 Odyssey Partners Ltd. Investment ManagersFinance Provides Investment advisers | Corporate Officer/Principal | 31/01/2007 |
Shire Human Genetic Therapies, Inc.
 Shire Human Genetic Therapies, Inc. Medical SpecialtiesHealth Technology Develops human genetic therapies | Corporate Officer/Principal | - |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 11 |
|---|---|
Vertex Pharmaceuticals, Inc.
 Vertex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops drugs for the treatment of cystic fibrosis | Health Technology |
Shire Plc /Old/
Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Develops, manufactures and markets pharmaceuticals | Commercial Services |
ACADIA Pharmaceuticals, Inc.
 ACADIA Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals drugs for treatment of central nervous system disorders | Health Technology |
Genocea Biosciences, Inc.
 Genocea Biosciences, Inc. BiotechnologyHealth Technology Operates as clinical stage biotechnology company that discovers and develops novel cancer immunotherapies | Health Technology |
Avanti Capital PLC
 Avanti Capital PLC Financial ConglomeratesFinance Provides investment management and ancillary services | Finance |
University of Durham
 University of Durham Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
London Business School
 London Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Odyssey Partners Ltd.
Odyssey Partners Ltd. Investment ManagersFinance Provides Investment advisers | Finance |
Shire Human Genetic Therapies, Inc.
Shire Human Genetic Therapies, Inc. Medical SpecialtiesHealth Technology Develops human genetic therapies | Health Technology |
Evelo Biosciences, Inc.
 Evelo Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Develops oral therapeutics for small intestine related diseases | Health Technology |
Codiak BioSciences, Inc.
 Codiak BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops exosome based therapeutics | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
